BioCentury
ARTICLE | Financial News

Taiwan Liposome planning NASDAQ listing

February 23, 2018 3:26 PM UTC

Drug delivery company Taiwan Liposome Co. Ltd. (TPEx:4152) proposed to raise up to $50 million on Feb. 17 through the sale of ADSs in a NASDAQ listing underwritten by Cantor Fitzgerald, CLSA, H.C. Wainwright, Janney Montgomery Scott and Laidlaw.

The company develops therapeutics using its BioSeizer lipid formulation technology, which is designed to enable increased pharmacokinetic control and local sustained release of APIs. Its lead program, TLC599, is a formulation of dexamethasone formulated with BioSeizer. Top-line data are due in 2H18 from an Australian Phase II study of the therapy to treat osteoarthritis pain of the knee; Taiwan Liposome hopes to begin a pivotal U.S. study in 1H19 in the indication...

BCIQ Company Profiles

Taiwan Liposome Co. Ltd.